Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AOD-9604 and Glutathione — mechanism, side effects, legal status, and pricing.
AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmaceuticals (Australia) to isolate a purported 'lipolytic' activity of GH without GH-receptor-mediated growth or diabetogenic effects. AOD-9604 is NOT FDA-approved for any indication; controlled human trials for obesity did not demonstrate clinically meaningful weight loss, and obesity development was terminated in 2007.
Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the principal intracellular antioxidant in mammalian cells. It is not FDA-approved as a drug in the US; parenteral glutathione is used off-label (and in some compounding settings) for oxidative stress, hepatic support, and — controversially — skin lightening. The FDA has warned against injectable glutathione for skin lightening (2019) due to reports of serious adverse events.
AOD-9604
Glutathione
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AOD-9604
Glutathione
COA corpus from Disclosed Labs — independently tested batches only.
AOD-9604
97
COAs
99.5%
Avg purity
16
Labs
Glutathione
62
COAs
99.5%
Avg purity
10
Labs
Clinical: AOD-9604 went through six randomized, double-blind, placebo-controlled Phase 1/2 trials across approximately 900 subjects (Stier et al., J Endocrinol Metab 2013). These established a safety profile indistinguishable from placebo — no effect on IGF-1, no impairment of glucose tolerance, no anti-AOD-9604 antibodies — but did NOT demonstrate clinically meaningful weight loss. A 24-week Phase 2b trial (~536 obese subjects) failed its primary efficacy endpoint and Metabolic Pharmaceuticals / Calzada terminated obesity development in 2007. Preclinical: Heffernan et al. (Int J Obes 2001, PMID 11673763; Endocrinology 2001, PMID 11713213) reported reduced body-weight gain and increased fat oxidation in obese mice and showed the lipolytic action did not require direct β3-AR agonism (β3-knock-out animals still responded). Ng et al. (Horm Res 2000, PMID 11146367) reported metabolic effects in obese Zucker rats without insulin-sensitivity impairment. Osteoarthritis exploration is limited to preclinical animal work — Kwon & Park (Ann Clin Lab Sci 2015, PMID 26275694) reported intra-articular AOD-9604 plus hyaluronic acid was superior to either alone in a collagenase-induced rabbit OA model; no adequately powered human OA trial has been published. Regulatory: NOT FDA-approved; widely-cited 'FDA GRAS' status has not been confirmed in the FDA GRAS Notice Inventory. PCAC voted AGAINST including AOD-9604 on the 503A Bulks List on December 4, 2024.
Key references
A randomized, double-blind pilot trial (Hauser et al., Movement Disorders, 2009, PMID 19230029) tested IV glutathione 1,400 mg three times weekly for 4 weeks in Parkinson's disease (n=21); it was well tolerated but did NOT show a statistically significant effect on UPDRS scores. A large randomized trial of inhaled glutathione (646 mg every 12 hours for 6 months) in cystic fibrosis (Griese et al., Am J Respir Crit Care Med, 2013, PMID 23631796) did not demonstrate clinically relevant improvements in lung function, exacerbations, or quality of life. Oral glutathione has poor bioavailability due to GI degradation, driving investigation of IV, nebulized, liposomal, and sublingual delivery. The FDA issued a 2019 warning about compounded sterile injectable glutathione made from dietary-grade ingredient, citing adverse-event reports (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and kidney dysfunction) particularly in the context of unregulated IV skin-lightening use.
AOD-9604 (Metabolic) and Glutathione (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs